Does Rallies show Form 4 insider transactions for SNDX?

Yes. Rallies tracks SNDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SNDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SNDX. It does not provide personalized investment advice.

SNDX (Syndax Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

Syndax Pharmaceuticals, Inc. (SNDX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNDX trades at $20.23 with a market cap of $1.72B and a P/E ratio of -6.10. SNDX moved +4.08% today. Year to date, SNDX is -0.45%; over the trailing twelve months it is +90.44%. Its 52-week range spans $8.58 to $25.59. Analyst consensus is strong buy with an average price target of $39.91. Rallies surfaces SNDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SNDX stock inside the company?

Recent SNDX insider activity includes Metzger Michael A sold 17.16K, Goldan Keith A. sold 3.41K, Metzger Michael A sold 7.41K, Goldan Keith A. sold 2.08K, and Metzger Michael A sold 157.31K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SNDX Key Metrics

Key financial metrics for SNDX
Metric	Value
Price	$20.23
Market Cap	$1.72B
P/E Ratio	-6.10
EPS	$-3.29
Dividend Yield	0.00%
52-Week High	$25.59
52-Week Low	$8.58
Volume	2
Avg Volume	0
Revenue (TTM)	$172.35M
Net Income	$-285.42M
Gross Margin	0.00%

Recent SNDX Insider Trades

Metzger Michael A sold 17.16K (~$360.82K) on Feb 9, 2026.
Goldan Keith A. sold 3.41K (~$71.71K) on Feb 9, 2026.
Metzger Michael A sold 7.41K (~$152.84K) on Feb 6, 2026.
Goldan Keith A. sold 2.08K (~$42.93K) on Feb 6, 2026.
Metzger Michael A sold 157.31K (~$2.58M) on Sep 8, 2025.

Latest SNDX News

Syndax Highlights 12 Revuforj Abstracts Accepted for EHA 2026 — May 12, 2026
Syndax Q1 Revenue $64.9M, 50% Transplant Rate Delays Maintenance Restarts — May 1, 2026
Syndax Q1 Revenue Soars 224% to $64.9M, Revuforj Hits $48.9M — Apr 30, 2026
Syndax’s Revuforj Q4 Revenue Jumps 38% to $44.2M, 1,050 Patients Treated — Feb 27, 2026
Syndax Posts $68.7M Q4, $172.4M FY25 Revenue; Revuforj Up 38%, Niktimvo Up 22% — Feb 26, 2026

SNDX Analyst Consensus

12 analysts cover SNDX: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.91.

Common questions about SNDX

Who is trading SNDX stock inside the company?: Recent SNDX insider activity includes Metzger Michael A sold 17.16K, Goldan Keith A. sold 3.41K, Metzger Michael A sold 7.41K, Goldan Keith A. sold 2.08K, and Metzger Michael A sold 157.31K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SNDX?: Yes. Rallies tracks SNDX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SNDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SNDX. It does not provide personalized investment advice.